Endeavor BioMedicines Presents New Quantitative Imaging Data from Analysis of Phase 2a Clinical Trial Evaluating Taladegib (ENV-101) in Patients with Idiopathic Pulmonary Fibrosis (Businesswire) - Sep 8, 2026 - "Taladegib and placebo groups were well matched at baseline based on WRVS, a measure of peripheral fibrosis severity. Taladegib mean WRVS at baseline was 15.5% and the placebo group was 14.2%. A baseline WRVS ≥ 15 indicates increased risk of FVC decline. Patients treated with taladegib experienced a statistically significant increase in lung volume compared with placebo. Mean change in lung volume was +204 mL improvement from baseline in the taladegib group compared with −60 mL in the placebo group (p=0.003)."
P2a data • Idiopathic Pulmonary Fibrosis
|